Cetrotide (cetrorelix)

The control group was treated intraperitoneally with saline, while the colitis groups were treated intraperitoneally with saline or PNX-14 (50 μg/kg/d) or gonadotrophin-releasing hormone (GnRH)-antagonist cetrorelix (CTX; 100µg/kg/d) or CTX and PNX-14 or sulfasalazine as a positive control (100mg/kg/d) instantly and once a day for 3 days following colitis induction. PNX-14, which alleviates macroscopic, histological and biochemical parameters, can be considered as a potential therapeutic agent in ulcerative colitis with its anti-inflammatory, antioxidant and anti-apoptotic actions. Furthermore, despite its effects as an GnRH-antagonist, CTX has also revealed a similar beneficial role as PNX-14 in this ulcerative colitis model.

P=N/A, N=1338, Recruiting, Northwest Women's and Children's Hospital, Xi'an, Shaanxi | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=328, Completed, Kasr El Aini Hospital

P=N/A, N=1266, Completed, The First Affiliated Hospital of Zhengzhou University | Unknown status --> Completed | N=50 --> 1266 | Trial completion date: Aug 2018 --> Dec 2024

P4, N=200, Completed, Henan Provincial People's Hospital; Henan Provincial People's Hospital | Not yet recruiting --> Completed

P1, N=22, Completed, University of Athens

P=N/A, N=297, Completed, Bezmialem Vakif University | Recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024

P=N/A, N=546, Completed, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University o | Recruiting --> Completed

P=N/A, N=240, Completed, Shanghai First Maternity and Infant Hospital | Trial completion date: Jul 2023 --> Feb 2024

P4, N=100, Recruiting, The University of Texas at Arlington | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

Our study underscores the potential reproductive implications of cetrorelix treatment prior to Anti-PD-L1 therapy, shedding light on its short-term protective effects on the uterus. Further studies are necessary to understand long-term and clinical implications.

The methods of treatment include surgical (myomectomy and hysterectomy, embolization of arteries) and therapeutic treatment (ulipristal acetate, leuprolide acetate, cetrorelix, goserelin, mifepristone). Three different nosological forms of the disease associated with driver mutations in the MED12, HMGA2, and FH genes should be considered when developing or prescribing drugs. For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules.